NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. The company reported quarterly sales of $977.65 thousand which beat the analyst consensus estimate of $852.00 thousand by 14.75 percent. This is a 753.25 percent increase over sales of $114.58 thousand the same period last year.
NeuroOne Medical Tech Q1 2024 GAAP EPS $(0.14), Inline, Sales $977.65K Beat $852.00K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.